Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
Shang‐Gin Wu, Wei‐Yu Liao, Kang‐Yi Su, Sung‐Liang Yu, Yen-Lin Huang, Chong‐Jen Yu, James Chih‐Hsin Yang, Jin‐Yuan Shih
Abstract
INTRODUCTION: mutation subtypes. METHODS: mutation analysis using direct Sanger sequencing or MassARRAY genotyping (Agena Bioscience, San Diego, CA) at the National Taiwan University Hospital. Clinical characteristics, ICI treatment effectiveness, time-to-tumor recurrence (TTR), and overall survival (OS) were analyzed using multivariate Cox models, to estimate adjusted hazard ratios (HRs). RESULTS: = 0.002). CONCLUSIONS: -G12C.
Topics & Concepts
KRASMedicineInternal medicineOncologyHazard ratioSanger sequencingStage (stratigraphy)CohortOverall survivalMutationCancerColorectal cancerBiologyConfidence intervalPaleontologyGeneBiochemistryCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies